Monte Rosa Therapeutics logo

Monte Rosa Therapeutics Share Price (NASDAQ: GLUE)

$4.8

-0.03

(-0.62%)

Last updated on

Check the interactive Monte Rosa Therapeutics Stock chart to analyse performance

Monte Rosa Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$4.76
    Today's High:$4.84

    Day's Volatility :1.76%

  • 52 Weeks Low:$3.50
    52 Weeks High:$12.40

    52 Weeks Volatility :71.77%

Monte Rosa Therapeutics Stock Returns

PeriodMonte Rosa Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
6.67%
3.6%
0.0%
6 Months
-13.51%
-7.7%
0.0%
1 Year
-17.53%
-12.6%
0.0%
3 Years
-42.03%
9.5%
-4.7%

Monte Rosa Therapeutics Inc Key Stats

Check Monte Rosa Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$4.83
Open
$4.83
Today's High
$4.84
Today's Low
$4.755
Market Capitalization
$298.3M
Today's Volume
$480.9K
52 Week High
$12.4
52 Week Low
$3.5001
Revenue TTM
$178.0M
EBITDA
$23.3M
Earnings Per Share (EPS)
$0.39
PE Ratio
12.38
Profit Margin
13.58%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
9.81%

Stock Returns calculator for Monte Rosa Therapeutics Stock including INR - Dollar returns

The Monte Rosa Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Monte Rosa Therapeutics investment value today

Current value as on today

₹87,758

Returns

₹12,242

(-12.24%)

Returns from Monte Rosa Therapeutics Stock

₹17,526 (-17.53%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Monte Rosa Therapeutics Stock

100%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Monte Rosa Therapeutics Stock from India on INDmoney has increased by 100% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Monte Rosa Therapeutics Inc

  • Name

    Holdings %

  • NEA Management Company, LLC

    12.46%

  • T. Rowe Price Associates, Inc.

    10.25%

  • Bvf Inc

    9.17%

  • Versant Venture Management LLC

    9.16%

  • Baker Bros Advisors LP

    7.97%

  • FMR Inc

    7.57%

Analyst Recommendation on Monte Rosa Therapeutics Stock

Rating
Trend

Buy

    92%Buy

    7%Hold

    0%Sell

Based on 14 Wall street analysts offering stock ratings for Monte Rosa Therapeutics(by analysts ranked 0 to 5 stars)

Monte Rosa Therapeutics Share Price Target

What analysts predicted

Upside of 218.45%

Target:

$15.29

Current:

$4.80

Monte Rosa Therapeutics share price target is $15.29, a slight Upside of 218.45% compared to current price of $4.80 as per analysts' prediction.

Monte Rosa Therapeutics Stock Insights

  • Price Movement

    In the last 1 month, GLUE stock has moved down by -14.0%
  • GLUE vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 92.1%
  • GLUE vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 151.9%
  • Price to Sales

    ForGLUE every $1 of sales, investors are willing to pay $2.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Monte Rosa Therapeutics Technicals Summary

Sell

Neutral

Buy

Monte Rosa Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Monte Rosa Therapeutics Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Monte Rosa Therapeutics Inc logo
-3.03%
-13.51%
-17.53%
-42.03%
-75.17%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
1.77%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
75.87%
111.28%
242.25%

About Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd. to discover and develop MGDs against targets in cancer and neurological diseases. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Organization
Monte Rosa Therapeutics
Employees
142
CEO
Dr. Markus Warmuth M.D.
Industry
Services

Key Management of Monte Rosa Therapeutics Inc

NameTitle
Dr. Markus Warmuth M.D.
President, CEO & Director
Mr. Philip Nickson J.D., Ph.D.
Chief Business & Legal Officer
Ms. Jennifer Champoux
Chief Operating Officer
Dr. John C. Castle Ph.D.
Chief Data & Information Officer
Dr. Sharon Townson Ph.D.
Chief Scientific Officer
Mr. Andrew Funderburk
Senior VP and Head of IR & Strategic Finance
Mr. Magnus Walter DPHIL
Senior Vice President of Drug Discovery
Mr. Edmund Dunn
Senior VP & Corporate Controller

Important FAQs about investing in GLUE Stock from India :

What is Monte Rosa Therapeutics share price today?

Monte Rosa Therapeutics share price today is $4.80 as on at the close of the market. Monte Rosa Therapeutics share today touched a day high of $4.84 and a low of $4.76.

What is the 52 week high and 52 week low for Monte Rosa Therapeutics share?

Monte Rosa Therapeutics share touched a 52 week high of $12.40 and a 52 week low of $3.50. Monte Rosa Therapeutics stock price today i.e. is closed at $4.80, lower by 61.29% versus the 52 week high.

How to invest in Monte Rosa Therapeutics Stock (GLUE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Monte Rosa Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Monte Rosa Therapeutics Shares that will get you 0.3125 shares as per Monte Rosa Therapeutics share price of $4.80 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Monte Rosa Therapeutics Stock (GLUE) from India?

Indian investors can start investing in Monte Rosa Therapeutics (GLUE) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Monte Rosa Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Monte Rosa Therapeutics share’s latest price of $4.80 as on August 30, 2025 at 1:29 am IST, you will get 2.0833 shares of Monte Rosa Therapeutics. Learn more about fractional shares .

What are the returns that Monte Rosa Therapeutics has given to Indian investors in the last 5 years?

Monte Rosa Therapeutics stock has given -75.17% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?